FDA Approves Dupilumab, Marking First Targeted Therapy in a Decade for Chronic Spontaneous Urticaria
Published: April 18th 2025 | Updated: April 18th 2025Multiple phase 3 clinical trials demonstrated dupilumab’s (Dupixent; Regeneron, Sanofi) effectiveness in reducing hives and itch in patients with chronic spontaneous urticaria compared with placebo.
FDA Grants Accelerated Approval to Atrasentan for Proteinuria Reduction in Primary IgA Nephropathy
April 3rd 2025Positive results from an interim analysis of the phase 3 ALIGN study bolstered atrasentan towards receiving accelerated approval for patients with immunoglobulin A nephropathy, a rare condition that can cause kidney failure.
First Antibody Therapy for Acute Myocardial Infarction Granted FDA Fast Track Designation
March 25th 2025If approved, this novel monoclonal antibody therapy could become a standard of care emergency option for patients with acute myocardial infarction, which affects millions in the United States and across the world.